PhRMA’s submission (7 February 2014, USTR-2013-0040) to USTR’s 2014 Special 301 Review requested USTR to have “Brazil remain on the Priority Watch List for the 2014 Special 301 Report” expressing concerns over Brazilian patentability standards, regulatory data protection, patent term adjustment for mailbox patents and government price controls and taxation.